Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience

Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Antonuzzo A, Luca G, Vasile E,

Keywords: everolimus SSA,

#1120 Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET

Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Galli L, Antonuzzo A, Vasile E,

Keywords: capecitabine, oxaliplatine ,

#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?

Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dussol A, Joly M, Hervieu V, Forestier J, Lombard-Bohas C,

Keywords: gemox, alkylating agent, MGMT,